Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2017

22.06.2017 | Epidemiology

Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease

verfasst von: Rhonda Arthur, Yihong Wang, Kenny Ye, Andrew G. Glass, Mindy Ginsberg, Olivier Loudig, Thomas Rohan

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Women with benign breast disease (BBD) have an increased risk of subsequent breast cancer. However, whether conventional breast cancer risk factors influence risk of breast cancer among women with BBD is unclear. In this study, we investigated the associations of lifestyle, menstrual/reproductive, and histological factors with risk of breast cancer among women biopsied for BBD.

Methods

We conducted a case–control study, nested within a cohort of 15,395 women biopsied for BBD at Kaiser Permanente Northwest between 1971 and 2006. Cases were women who developed a subsequent invasive breast cancer during follow-up; controls were individually matched to cases on age at BBD diagnosis. A total of 526 case–control pairs were included in the study. We calculated crude and multivariable OR and 95% CI for the associations between lifestyle, menstrual/reproductive, and histological factors and breast cancer risk using conditional logistic regression.

Results

Compared to premenopausal women, postmenopausal women had reduced risk of subsequent breast cancer (OR 0.60; 95% CI 0.39–0.94), whereas women who ever used hormone replacement therapy (HRT) had increased risk (OR 3.61; 95% CI 1.68–7.75), as did women whose BBD lesion showed atypical hyperplasia (OR 5.56; 95% CI 2.05–15.06). Smoking, BMI, early menarche, multiparity (≥4), history of oophorectomy, and extent of lobular involution were not associated with risk of breast cancer.

Conclusion

This study suggests that use of HRT and having atypical hyperplasia are associated with increased risk of breast cancer among women with BBD, while postmenopausal women with BBD have a reduced risk.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Goldacre MJ, Abisgold JD, Yeates DGR, Vessey MP (2010) Benign breast disease and subsequent breast cancer: English record linkage studies. J Public Health Med 32:565–571. doi:10.1093/pubmed/fdq001 CrossRef Goldacre MJ, Abisgold JD, Yeates DGR, Vessey MP (2010) Benign breast disease and subsequent breast cancer: English record linkage studies. J Public Health Med 32:565–571. doi:10.​1093/​pubmed/​fdq001 CrossRef
8.
Zurück zum Zitat Horn-Ross P, Canchola AJ, West DW, Stewart SL, Bernstein L, Deapen D et al (2004) Patterns of alcohol consumption and breast cancer risk in the california teachers study cohort. Cancer Epidemiol Biomarkers Prev 13:405PubMed Horn-Ross P, Canchola AJ, West DW, Stewart SL, Bernstein L, Deapen D et al (2004) Patterns of alcohol consumption and breast cancer risk in the california teachers study cohort. Cancer Epidemiol Biomarkers Prev 13:405PubMed
10.
12.
Zurück zum Zitat Rothman K, Greenland S, Lash T (2008) Modern epidemiology. Lippincott Williams & Wilkins, Philadelphia Rothman K, Greenland S, Lash T (2008) Modern epidemiology. Lippincott Williams & Wilkins, Philadelphia
14.
Zurück zum Zitat Page OL, Anderson TJ (1987) Diagnostic histopathology of the breast. Churchill Livingstone, Edinburgh Page OL, Anderson TJ (1987) Diagnostic histopathology of the breast. Churchill Livingstone, Edinburgh
16.
17.
Zurück zum Zitat Collins LC, Baer HJ, Tamimi RM, Connolly JL, Colditz GA, Schnitt SJ (2006) The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease. Cancer 107:1240–1247. doi:10.1002/cncr.22136 CrossRefPubMed Collins LC, Baer HJ, Tamimi RM, Connolly JL, Colditz GA, Schnitt SJ (2006) The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease. Cancer 107:1240–1247. doi:10.​1002/​cncr.​22136 CrossRefPubMed
20.
Zurück zum Zitat Dossus L, Boutron-Ruault M, Kaaks R, Gram IT, Vilier A, Fervers B et al (2014) Active and passive cigarette smoking and breast cancer risk: results from the EPIC cohort. Int J Cancer 134:1871–1888. doi:10.1002/ijc.28508 CrossRefPubMed Dossus L, Boutron-Ruault M, Kaaks R, Gram IT, Vilier A, Fervers B et al (2014) Active and passive cigarette smoking and breast cancer risk: results from the EPIC cohort. Int J Cancer 134:1871–1888. doi:10.​1002/​ijc.​28508 CrossRefPubMed
21.
Zurück zum Zitat Johnson KC, Miller AB, Collishaw NE, Palmer JR, Hammond SK, Salmon AG et al (2011) Active smoking and secondhand smoke increase breast cancer risk: the report of the Canadian expert panel on tobacco smoke and breast cancer risk (2009). Tob Control 20:e2. doi:10.1136/tc.2010.035931 CrossRefPubMed Johnson KC, Miller AB, Collishaw NE, Palmer JR, Hammond SK, Salmon AG et al (2011) Active smoking and secondhand smoke increase breast cancer risk: the report of the Canadian expert panel on tobacco smoke and breast cancer risk (2009). Tob Control 20:e2. doi:10.​1136/​tc.​2010.​035931 CrossRefPubMed
26.
27.
Zurück zum Zitat Castells X, Domingo L, Corominas JM, Torá-Rocamora I, Quintana MJ, Baré M et al (2015) Breast cancer risk after diagnosis by screening mammography of nonproliferative or proliferative benign breast disease: a study from a population-based screening program. Breast Cancer Res Treat 149:237–244. doi:10.1007/s10549-014-3208-z CrossRefPubMed Castells X, Domingo L, Corominas JM, Torá-Rocamora I, Quintana MJ, Baré M et al (2015) Breast cancer risk after diagnosis by screening mammography of nonproliferative or proliferative benign breast disease: a study from a population-based screening program. Breast Cancer Res Treat 149:237–244. doi:10.​1007/​s10549-014-3208-z CrossRefPubMed
29.
Zurück zum Zitat Monninkhof EM, van der Schouw YT, Peeters PHM (1999) Early age at menopause and breast cancer: are leaner women more protected? A prospective analysis of the Dutch DOM cohort. Breast Cancer Res Treat 55:285–291. doi:10.1023/A:1006277207963 CrossRefPubMed Monninkhof EM, van der Schouw YT, Peeters PHM (1999) Early age at menopause and breast cancer: are leaner women more protected? A prospective analysis of the Dutch DOM cohort. Breast Cancer Res Treat 55:285–291. doi:10.​1023/​A:​1006277207963 CrossRefPubMed
33.
Zurück zum Zitat Gambrel RJ, Maier R, Sanders B (1983) Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol 62:435–443 Gambrel RJ, Maier R, Sanders B (1983) Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol 62:435–443
34.
Zurück zum Zitat Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 350:1047–1059. doi:10.1016/S0140-6736(97)08233-0 CrossRef Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 350:1047–1059. doi:10.​1016/​S0140-6736(97)08233-0 CrossRef
35.
Zurück zum Zitat Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH et al (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. J Am Med Assoc 304:1684–1692. doi:10.1001/jama.2010.1500 CrossRef Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH et al (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. J Am Med Assoc 304:1684–1692. doi:10.​1001/​jama.​2010.​1500 CrossRef
36.
Zurück zum Zitat Thorbjarnardottir T, Olafsdottir EJ, Valdimarsdottir UA, Olafsson O, Tryggvadottir L (2014) Oral contraceptives, hormone replacement therapy and breast cancer risk: a cohort study of 16 928 women 48 years and older. Acta Oncol 53:752–758. doi:10.3109/0284186X.2013.878471 CrossRefPubMed Thorbjarnardottir T, Olafsdottir EJ, Valdimarsdottir UA, Olafsson O, Tryggvadottir L (2014) Oral contraceptives, hormone replacement therapy and breast cancer risk: a cohort study of 16 928 women 48 years and older. Acta Oncol 53:752–758. doi:10.​3109/​0284186X.​2013.​878471 CrossRefPubMed
41.
Zurück zum Zitat Russo J, Fernandez SV, Russo PA, Fernbaugh R, Sheriff FS, Lareef HM et al (2006) 17-Beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells. FASEB J 20:1622–1634. doi:10.1096/fj.05-5399com CrossRefPubMed Russo J, Fernandez SV, Russo PA, Fernbaugh R, Sheriff FS, Lareef HM et al (2006) 17-Beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells. FASEB J 20:1622–1634. doi:10.​1096/​fj.​05-5399com CrossRefPubMed
Metadaten
Titel
Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease
verfasst von
Rhonda Arthur
Yihong Wang
Kenny Ye
Andrew G. Glass
Mindy Ginsberg
Olivier Loudig
Thomas Rohan
Publikationsdatum
22.06.2017
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2017
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4347-9

Weitere Artikel der Ausgabe 3/2017

Breast Cancer Research and Treatment 3/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.